Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has signed a definitive equipment order and ...

High BP Alert: Can your arm position skew Blood Pressure readings? Experts share correct techniques for accurate results

High blood pressure continues to be a leading risk factor for heart disease, stroke, and kidney failure across the globe. Now ...
The Lancet

Treatment for Alzheimer's disease

Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with ...
The Business Standard

Bangladesh’s first Robotic Rehabilitation Centre: Ushering in a new era of physiotherapy treatment

In a groundbreaking step for Bangladesh’s healthcare system, the country has inaugurated its first Robotic Rehabilitation Centre. Combining cutting-edge robotics and AI, the centre promises more ...

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK ...